Therapeutic cancer vaccines: a long and winding road to success

Area of Science:

• Oncology
• Immunology

Background:

• Cancer immuno-oncology leverages the immune system for therapeutic efficacy.
• Tumor-induced immunosuppression hinders immunotherapy effectiveness.
• Understanding cancer immunoediting informs immunotherapy strategies.

Purpose of the Study:

• To review promising cancer vaccination platforms.
• To discuss essential perspectives in cancer immunotherapy.
• To highlight the combination of vaccines with other therapies.

Main Methods:

• Review of current literature on cancer vaccines and immunotherapy.
• Analysis of strategies combining vaccines with chemotherapy and checkpoint inhibitors.
• Examination of evidence for early-stage cancer vaccine administration.

Main Results:

• Combining cancer vaccines with chemotherapy can counteract tumor-induced suppression and show clinical efficacy.
• Targeting co-inhibitory and co-stimulatory receptors with antibodies shows promise, especially when combined with vaccines.
• Evidence suggests vaccine administration in early-stage, less aggressive disease warrants further investigation.

Conclusions:

• Cancer vaccines, particularly when combined with chemotherapy or checkpoint inhibitors, represent a promising immunotherapy approach.
• Identifying appropriate patient populations and early markers of clinical benefit is crucial for vaccine therapy.
• Further research into vaccination platforms and patient selection is essential for advancing cancer treatment.